RS57962B1 - Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze - Google Patents
Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenazeInfo
- Publication number
- RS57962B1 RS57962B1 RS20181322A RSP20181322A RS57962B1 RS 57962 B1 RS57962 B1 RS 57962B1 RS 20181322 A RS20181322 A RS 20181322A RS P20181322 A RSP20181322 A RS P20181322A RS 57962 B1 RS57962 B1 RS 57962B1
- Authority
- RS
- Serbia
- Prior art keywords
- benzotriazole derivatives
- oxygenase inhibitors
- trisubstituted benzotriazole
- dihydroorotate oxygenase
- dihydroorotate
- Prior art date
Links
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 title 1
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 title 1
- 239000003650 oxygenase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN825CH2013 | 2013-02-25 | ||
| EP14754772.3A EP3019482B1 (en) | 2013-02-25 | 2014-02-24 | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| PCT/IB2014/059204 WO2014128669A2 (en) | 2013-02-25 | 2014-02-24 | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS57962B1 true RS57962B1 (sr) | 2019-01-31 |
Family
ID=51391932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20181322A RS57962B1 (sr) | 2013-02-25 | 2014-02-24 | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9630932B2 (sr) |
| EP (2) | EP3417850A1 (sr) |
| CY (1) | CY1120826T1 (sr) |
| DK (1) | DK3019482T3 (sr) |
| ES (1) | ES2694829T3 (sr) |
| HR (1) | HRP20181908T1 (sr) |
| HU (1) | HUE042032T2 (sr) |
| LT (1) | LT3019482T (sr) |
| PL (1) | PL3019482T3 (sr) |
| PT (1) | PT3019482T (sr) |
| RS (1) | RS57962B1 (sr) |
| SI (1) | SI3019482T1 (sr) |
| WO (1) | WO2014128669A2 (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57962B1 (sr) | 2013-02-25 | 2019-01-31 | Aurigene Discovery Tech Ltd | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US20190192501A1 (en) * | 2016-08-23 | 2019-06-27 | Icahn School Of Medicine At Mount Sinai | Methods for treating pten-mutant tumors |
| JP2019535689A (ja) | 2016-10-27 | 2019-12-12 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ４，５−縮環１，２，４−トリアゾロン |
| AU2018223982B2 (en) | 2017-02-24 | 2022-02-03 | Merck Patent Gmbh | 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| MA48459B1 (fr) * | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| JP7434185B2 (ja) * | 2018-02-20 | 2024-02-20 | レ ラボラトワール セルヴィエ | 三置換ベンゾトリアゾール誘導体の使用方法 |
| EP4438042A2 (en) | 2018-06-22 | 2024-10-02 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
| MX2021003731A (es) | 2018-09-28 | 2021-08-05 | Acucela Inc | Inhibidores de vap-1. |
| MX2021003559A (es) * | 2018-09-28 | 2021-08-24 | Acucela Inc | Inhibidores de vap-1. |
| CA3124401A1 (en) * | 2018-12-21 | 2020-06-25 | Les Laboratoires Servier | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| JP2023533489A (ja) | 2020-06-24 | 2023-08-03 | レ ラボラトワール セルビエ | 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用 |
| US20230285365A1 (en) | 2020-08-27 | 2023-09-14 | Servier Pharmaceuticals Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| WO2022167402A1 (en) | 2021-02-02 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor |
| WO2023280181A1 (zh) * | 2021-07-05 | 2023-01-12 | 微境生物医药科技(上海)有限公司 | 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| DE102005049953A1 (de) * | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| KR101177729B1 (ko) * | 2006-09-08 | 2012-09-07 | 에프. 호프만-라 로슈 아게 | 벤조트리아졸 키나아제 조절제 |
| EP2387568A1 (en) * | 2009-01-19 | 2011-11-23 | NeuroSearch A/S | Novel benzotriazole derivatives useful for the treatment of cns disorders |
| SG10201401169QA (en) * | 2009-04-02 | 2014-05-29 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| RS57962B1 (sr) | 2013-02-25 | 2019-01-31 | Aurigene Discovery Tech Ltd | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
-
2014
- 2014-02-24 RS RS20181322A patent/RS57962B1/sr unknown
- 2014-02-24 DK DK14754772.3T patent/DK3019482T3/en active
- 2014-02-24 LT LTEP14754772.3T patent/LT3019482T/lt unknown
- 2014-02-24 US US14/784,708 patent/US9630932B2/en active Active
- 2014-02-24 EP EP18185083.5A patent/EP3417850A1/en not_active Withdrawn
- 2014-02-24 WO PCT/IB2014/059204 patent/WO2014128669A2/en active Application Filing
- 2014-02-24 SI SI201430904T patent/SI3019482T1/sl unknown
- 2014-02-24 ES ES14754772.3T patent/ES2694829T3/es active Active
- 2014-02-24 EP EP14754772.3A patent/EP3019482B1/en active Active
- 2014-02-24 PL PL14754772T patent/PL3019482T3/pl unknown
- 2014-02-24 HU HUE14754772A patent/HUE042032T2/hu unknown
- 2014-02-24 PT PT14754772T patent/PT3019482T/pt unknown
-
2017
- 2017-04-24 US US15/494,820 patent/US9937155B2/en active Active
- 2017-09-28 US US15/718,961 patent/US10080740B2/en active Active
-
2018
- 2018-09-07 US US16/124,578 patent/US20190105304A1/en not_active Abandoned
- 2018-11-07 CY CY181101172T patent/CY1120826T1/el unknown
- 2018-11-14 HR HRP20181908TT patent/HRP20181908T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20181908T1 (hr) | 2019-01-11 |
| PT3019482T (pt) | 2018-11-28 |
| HUE042032T2 (hu) | 2019-06-28 |
| EP3019482A2 (en) | 2016-05-18 |
| ES2694829T3 (es) | 2018-12-27 |
| WO2014128669A2 (en) | 2014-08-28 |
| WO2014128669A3 (en) | 2017-01-12 |
| CY1120826T1 (el) | 2019-12-11 |
| US20170224663A1 (en) | 2017-08-10 |
| LT3019482T (lt) | 2018-11-26 |
| US9937155B2 (en) | 2018-04-10 |
| EP3019482A4 (en) | 2017-05-10 |
| US20180021311A1 (en) | 2018-01-25 |
| EP3417850A1 (en) | 2018-12-26 |
| DK3019482T3 (en) | 2018-11-12 |
| US20160200693A1 (en) | 2016-07-14 |
| EP3019482B1 (en) | 2018-08-15 |
| SI3019482T1 (sl) | 2018-12-31 |
| US9630932B2 (en) | 2017-04-25 |
| US20190105304A1 (en) | 2019-04-11 |
| PL3019482T3 (pl) | 2019-02-28 |
| US10080740B2 (en) | 2018-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181908T1 (hr) | Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze | |
| HK1256999A1 (zh) | Syk抑制劑 | |
| IL243578A0 (en) | syk inhibitors | |
| SI2970272T1 (sl) | Inhibitorji glikozidaze | |
| EP2970340A4 (en) | BETA-Lactamase INHIBITORS | |
| EP2943204A4 (en) | BETA-Lactamase INHIBITORS | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| HK1220185A1 (zh) | 作爲 抑制劑的被取代的萘啶和喹啉化合物 | |
| EP3049435A4 (en) | Factor xia inhibitors | |
| EP3054944A4 (en) | FACTOR XIa INHIBITORS | |
| HK1209105A1 (en) | Vegfr3 inhibitors vegfr3 | |
| HK1209104A1 (en) | Vegfr3 inhibitors vegfr3 | |
| HK1213885A1 (zh) | 作為 抑制劑的咪唑並-三嗪衍生物 | |
| EP2968324A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS | |
| EP3010913A4 (en) | Piperidinolbenzimidazole derivatives as MPGE-1 inhibitors |